Abstract | BACKGROUND: PATIENTS AND RESULTS: We present a 10-year-old girl whose facial angiofibromas were successfully treated with an everolimus ointment without relevant side effects. In addition, we provide a short pharmacological overview of sirolimus and everolimus with focus on the topical use. CONCLUSIONS: Topical everolimus seems to be a favorable and safe option for patients with facial angiofibromas who do not require systemic treatment.
|
Authors | Patricia E Dill, Gaston De Bernardis, Peter Weber, Uli Lösch |
Journal | Pediatric neurology
(Pediatr Neurol)
Vol. 51
Issue 1
Pg. 109-13
(Jul 2014)
ISSN: 1873-5150 [Electronic] United States |
PMID | 24810875
(Publication Type: Case Reports, Journal Article)
|
Copyright | Copyright © 2014 Elsevier Inc. All rights reserved. |
Chemical References |
- Immunosuppressive Agents
- Everolimus
- Sirolimus
|
Topics |
- Angiofibroma
(etiology)
- Child
- Everolimus
- Face
(pathology)
- Female
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Sirolimus
(analogs & derivatives, therapeutic use)
- Tuberous Sclerosis
(complications)
|